- USPLabs agrees to recall and destroy dietary supplement following FDA actions
- Senate passes Drug Quality and Security Act
- FDA advisory committees vote against changing naproxen label to highlight a lower CVD profile
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- FDA advisory panel to consider OTC status of NSAIDs
RARITAN, N.J. The Food and Drug Administration turned down a regulatory approval application from Johnson & Johnson for a drug to treat chronic pain, J&J said Monday.
The drug maker said the FDA issued a complete response letter for tapentadol extended-release tablets. The agency is requesting data concerning the conversion of the extended-release formulation of the drug used in clinical trials to a different formulation designed to increase the drug’s resistance to breaking or crushing by drug abusers. The FDA issues a complete response letter when it needs more data before it can approve a drug.
“We will engage the FDA in active discussions as quickly as possible so that we can address the requests in the complete response letter,” Johnson & Johnson pharmaceutical research and development therapeutic area head for analgesia Juergen Haeussler said. “We remain fully committed to bringing tapentadol ER to patients experiencing chronic pain as quickly as possible.”